(PharmaNewsWire.Com, January 16, 2021 ) According to the new market research report "Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024", published by MarketsandMarkets™, the global DNA Synthesis Market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7% during the forecast period.
Don't miss out on business opportunities in Oligonucleotide Synthesis Market
The factors supporting DNA synthesis market growth include the increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for synthesized oligos in molecular diagnostics & therapeutics, rising venture capital investments, and the increasing demand for synthetic genes.
Therapeutic applications segment to grow at the highest CAGR during the forecast period
Based on application, the Oligonucleotide Synthesis Industry is segmented into research, diagnostic, and therapeutic applications. The therapeutic applications segment, which is further segmented into DNA & antisense oligonucleotide-based therapies, RNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies, is estimated to witness the highest growth during the forecast period. This can primarily be attributed to the investments by companies to explore the therapeutic applications of oligos. Also, from 2016 to 2018, more than five oligonucleotide-based therapies were approved by the FDA. In 2018, these oligonucleotide-based drugs generated a revenue of ~USD 2 billion. Apart from this, there are a couple of oligonucleotide-based drugs in Phase III and FDA review, and these drugs might be launched in the next five years and may positively impact DNA synthesis market.
Browse in-depth TOC on "Oligonucleotide Synthesis Market"
157 – Tables 39 – Figures 225 – Pages
Hospitals accounted for the largest share of the Oligonucleotide Synthesis Market, by end user, in 2018
Based on end user, the DNA Synthesis Industry is segmented into academic research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, and hospitals. Hospitals accounted for the largest share of the DNA Synthesis Market in 2018. Growth in this end-user segment is largely driven by the significant number of inpatient and outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the demand from the vast patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease.
North America was the largest regional market for oligonucleotide synthesis in 2018
The Oligonucleotide Synthesis Market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the DNA Synthesis Market majorly due to the availability of funds for research from various public- and private-sector organizations in the region and the focus of various prominent players on strengthening their presence in North America through product launches and strategic acquisitions and collaborations & agreements. Europe was the second-largest regional market for oligonucleotide synthesis in 2018. This can be attributed to factors such as the presence of a large number of academic and research institutes in the region, growing investments by government bodies and market players, and the increasing focus on R&D activities.
The prominent players in the Oligonucleotide Synthesis Market include Agilent Technologies, Inc. (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), BioAutomation Corporation (US), LGC Biosearch Technologies (US), Eurofins Genomics (Germany), Eurogentec (Belgium), GeneDesign, Inc. (Japan), GE Healthcare (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), TriLink BioTechnologies (US), and Sigma-Aldrich Corporation (US) (a part of Merck KGAA).
Sigma-Aldrich Corporation (US) was one of the leading players in the oligonucleotide synthesis market in 2018. The company is innovation-centric and focuses on R&D to develop and introduce new enhanced products in the DNA synthesis market. It is a leading supplier of custom DNA and RNA oligonucleotides for the life sciences research community in North America.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
